Literature DB >> 15271928

Chronic Helicobacter pylori infection with Sydney strain 1 and a newly identified mouse-adapted strain (Sydney strain 2000) in C57BL/6 and BALB/c mice.

Lucinda J Thompson1, Stephen J Danon, John E Wilson, Jani L O'Rourke, Nina R Salama, Stanley Falkow, Hazel Mitchell, Adrian Lee.   

Abstract

The mouse model of Helicobacter pylori-induced disease using Sydney strain 1 (SS1) has been used extensively in Helicobacter research. Herein we describe the isolation and characterization of a new mouse-colonizing strain for use in comparative studies. One strain capable of persistent mouse colonization was isolated from a total of 110 clinical isolates and is named here SS2000 (Sydney strain 2000). Genome typing revealed a number of differences between SS1 and SS2000 as well as between them and the respective original clinical isolates. In particular, SS2000 lacked the entire cag pathogenicity island, while SS1 contained all 27 genes of the island. C57BL/6 and BALB/c mice were infected with SS1 or SS2000 or were treated with broth medium (controls). After 6 months host-specific effects were evident, including lower colonization levels in the BALB/c animals. Few pathological differences were observed between SS1- and SS2000-infected animals. However, by 15 months postinfection, SS1-infected C57BL/6 mice had developed more severe gastritis than the SS2000-infected animals. In contrast SS2000-infected BALB/c mice showed increased accumulation of mucosa-associated lymphoid tissue compared to those infected with SS1. This improved comparative model of H. pylori-induced disease allowed dissection of both host and strain effects and thus will prove useful in further studies.

Entities:  

Mesh:

Year:  2004        PMID: 15271928      PMCID: PMC470698          DOI: 10.1128/IAI.72.8.4668-4679.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses.

Authors:  D A Israel; N Salama; C N Arnold; S F Moss; T Ando; H P Wirth; K T Tham; M Camorlinga; M J Blaser; S Falkow; R M Peek
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy.

Authors:  J S Kim; J H Chang; S I Chung; J S Yum
Journal:  FEMS Immunol Med Microbiol       Date:  2001-07

3.  Role of Helicobacter pylori cag region genes in colonization and gastritis in two animal models.

Authors:  K A Eaton; D Kersulyte; M Mefford; S J Danon; S Krakowka; D E Berg
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  A small animal model of human Helicobacter pylori active chronic gastritis.

Authors:  A Lee; J G Fox; G Otto; J Murphy
Journal:  Gastroenterology       Date:  1990-11       Impact factor: 22.682

5.  Infection with cagA- and vacA-positive and -negative strains of Helicobacter pylori in a mouse model.

Authors:  E Sturegård; H Sjunnesson; H Nilsson; R Andersson; C Areskoug; T Wadström
Journal:  FEMS Immunol Med Microbiol       Date:  2001-03

6.  gamma-Glutamyltransferase is a Helicobacter pylori virulence factor but is not essential for colonization.

Authors:  K J McGovern; T G Blanchard; J A Gutierrez; S J Czinn; S Krakowka; P Youngman
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  Comparison of gastritis and gastric epithelial proliferation in Helicobacter heilmannii-infected nude and BALB/c mice.

Authors:  R A Peterson; S J Danon; K A Eaton
Journal:  Vet Pathol       Date:  2001-03       Impact factor: 2.221

8.  DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting.

Authors:  N Akopyanz; N O Bukanov; T U Westblom; S Kresovich; D E Berg
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

9.  MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma.

Authors:  A Enno; J L O'Rourke; C R Howlett; A Jack; M F Dixon; A Lee
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

10.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

Authors:  M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

View more
  42 in total

1.  A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence.

Authors:  M S Alam; C C Kurtz; J M Wilson; B R Burnette; E B Wiznerowicz; W G Ross; J M Rieger; R A Figler; J Linden; S E Crowe; P B Ernst
Journal:  Mucosal Immunol       Date:  2009-03-04       Impact factor: 7.313

Review 2.  Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses.

Authors:  Holly M Scott Algood; Timothy L Cover
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  Gastric de novo Muc13 expression and spasmolytic polypeptide-expressing metaplasia during Helicobacter heilmannii infection.

Authors:  Cheng Liu; Annemieke Smet; Caroline Blaecher; Bram Flahou; Richard Ducatelle; Sara Linden; Freddy Haesebrouck
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

4.  HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model.

Authors:  Steven F Moss; Leonard Moise; Dong Soo Lee; Woojin Kim; Songhua Zhang; Jinhee Lee; Arlin B Rogers; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

5.  Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.

Authors:  Marygorret Obonyo; Li Zhang; Soracha Thamphiwatana; Dissaya Pornpattananangkul; Victoria Fu; Liangfang Zhang
Journal:  Mol Pharm       Date:  2012-08-06       Impact factor: 4.939

6.  Helicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activation.

Authors:  Takashi Joh; Hiromi Kataoka; Satoshi Tanida; Katsushi Watanabe; Tadayuki Ohshima; Makoto Sasaki; Haruhisa Nakao; Hirotaka Ohhara; Shigeki Higashiyama; Makoto Itoh
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 7.  Recapitulating Human Gastric Cancer Pathogenesis: Experimental Models of Gastric Cancer.

Authors:  Lin Ding; Mohamad El Zaatari; Juanita L Merchant
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

8.  Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2 -/- C57BL6 x Sv129 Helicobacter pylori-infected mice.

Authors:  James G Fox; Arlin B Rogers; Mark T Whary; Zhongming Ge; Masa Ohtani; Evelyn Kurt Jones; Timothy C Wang
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

9.  Loss of gastrokine-2 drives premalignant gastric inflammation and tumor progression.

Authors:  Trevelyan R Menheniott; Louise O'Connor; Yok Teng Chionh; Jan Däbritz; Michelle Scurr; Benjamin N Rollo; Garrett Z Ng; Shelley Jacobs; Angelique Catubig; Bayzar Kurklu; Stephen Mercer; Toshinari Minamoto; David E Ong; Richard L Ferrero; James G Fox; Timothy C Wang; Philip Sutton; Louise M Judd; Andrew S Giraud
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

10.  Molecular characterization of Helicobacter pylori VacA induction of IL-8 in U937 cells reveals a prominent role for p38MAPK in activating transcription factor-2, cAMP response element binding protein, and NF-kappaB activation.

Authors:  Junzo Hisatsune; Masaaki Nakayama; Hajime Isomoto; Hisao Kurazono; Naofumi Mukaida; Asish K Mukhopadhyay; Takeshi Azuma; Yoshio Yamaoka; Jan Sap; Eiki Yamasaki; Kinnosuke Yahiro; Joel Moss; Toshiya Hirayama
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.